DIU JOURNAL OF ALLIED HEALTH SCIENCES

MINI REVIEW
DIUJAHS. 2023 July; 10(2): 28-35
ISSN: 2408-9915 (Print)
ISSN: 2789-3847 (Online)
https://doi.org/10.36481/diujahs.v10i2.3b5z7d81
Published by
www.diujahs.daffodilvarsity.edu.bd

Navigating the Challenges of Antimicrobial Resistance: Epidemiological Insights and Strategic Solution

Safayet Jamil [1,2*]

[1] Department of Public Health, Daffodil International University, Dhaka 1216, Bangladesh.
[2] Department of Public and Community Health, Faculty of Medicine and Health Sciences, Frontier University Garowe, Puntland, Somalia.

Corresponding author*
Safayet Jamil
Department of Public Health,
Daffodil International University,
Dhaka 1216, Bangladesh.
Email:safayetkyau333@gmail.com

Article info
Received: 21 August 2023
Accepted: 15 October 2023
Published: 20 November 2023

Keywords
Antimicrobial resistance, Antibiotics, Epidemiology, Drug resistance.

ABSTRACT

Antimicrobial resistance (AMR) poses a significant global threat, compromising the effectiveness of antibiotics and leading to increased morbidity, mortality, and healthcare costs. This review examines the epidemiology, mechanisms, and challenges of AMR while highlighting strategic solutions. AMR emerges through bacterial mutations, horizontal gene transfer, and selection pressure caused by inappropriate antimicrobial use in medicine and agriculture. It affects millions annually, with projections of 10 million deaths by 2050 if unaddressed. Key challenges include over prescription, lack of new antibiotics, weak surveillance, and insufficient infection control. Solutions emphasize antimicrobial stewardship, enhanced surveillance, research into novel therapies, public awareness, and global collaboration under the "One Health" approach. Natural products are highlighted as promising alternatives for combating resistant pathogens. Coordinated efforts across governments, healthcare providers, and communities are essential to mitigate AMR and ensure effective treatment of infectious diseases. This article provides a comprehensive framework for addressing AMR through sustainable and collaborative interventions.

INTRODUCTION

The development of antimicrobial resistance (AMR) is becoming an increasing global problem for public health. Antibiotics have been used inappropriately and excessively, which has led to the development of drug-resistant bacteria (Van Boeckel et al, 2015). This has made it far more difficult to treat infectious infections. The hunt for new antimicrobial agents has become more intense in recent years, and natural products have emerged as a viable source of molecules that have antibacterial capabilities (Murray et al.,2022). The purpose of this article is to provide an overview of epidemiology, challenges and way forward of antimicrobial resistance.

Antibiotics have been a game-changer for contemporary medicine throughout the course of the last century, as they have provided an efficient therapy for bacterial infections. On the other hand, the overuse of antibiotics has resulted in the development and dissemination of bacteria that are resistant to the drugs that are used to treat them, making it more difficult to treat infectious infections (Aljeldah, 2022). It is now well acknowledged that AMR poses a threat to public health on a worldwide scale and calls for immediate response. According to the World Health Organization (WHO), AMR is responsible for an estimated 700,000 fatalities each year around the globe. If adequate actions are not implemented, this number is anticipated to climb to 10 million by the year 2050 (Chokshi et al.,2019; Mendelson and Matsoso, 2015).

Antimicrobial resistance (AMR) can develop in the human body through a variety of different methods, such as the acquisition of resistance genes, the mutation of bacteria, or choosing of resistant strains that already exist. The accumulation of resistant gene variants is one of the most important contributors to the development of AMR. Horizontal gene transfer, often known as the exchange of genetic material between different bacterial species, is one way that resistant gene variants can be acquired by bacteria. This mutation can take place by methods such as plasmid transfer or transduction, in which bacteriophages, which are viruses that infect bacteria, transfer DNA from one bacterial population to another. Mutations, which are modifications in the genetic material of the bacterium, can also contribute to the acquisition of resistance genes. These mutations can lead to alterations in the bacteria's physiology, including an increased capacity to withstand the effects of antimicrobial drugs. Mutations can occur naturally or as a result of selection pressure, such as being exposed to antibiotics. Both of these scenarios can result in the formation of mutations. AMR can also evolve through a process known as "selection of pre-existing resistant strains of bacteria," which is a different mechanism. In this instance, the use of antibiotics or other antimicrobial agents can select for the growth of bacteria that are resistant to the effects of the antimicrobials, permitting these germs to proliferate and spread. This can happen when antibiotics are handled incorrectly or when bacteria are exposed to sub-lethal doses of antibiotics, which can create selective pressure for the formation of resistant forms of bacteria. AMR can also develop in the gut microbiome, which is the collection of microorganisms that dwell in the human gut. These pathways are in addition to those that have already been discussed. The use of antibiotics can throw off the equilibrium of the microbiome in the gut, which opens the door for bacteria that are resistant to the drug to thrive and colonize the area. These antibiotic-resistant bacteria are capable of propagating to other areas of the body or being passed on to other people (Darby et al.,2022; Nathan, 2020; Larsson and Flach, 2022).

The main factors leading to antibiotic resistance are the careless and excessive use of antibiotics in both human medicine and agricultural settings. Some of the causes of antibiotic resistance include improper administration of antibiotics by medical professionals, the interest in antibiotics among patients, and the use of antibiotics as stimulants of growth in agricultural settings (Tiseo et al.,2020). The rise of germs that are resistant to many drugs has decreased the number of antibiotics that are now available, as well as enhanced the difficulty and expense of treatment (Kim and Cha, 2021).

The discovery of new antimicrobial agents has risen to the top of the research agenda on a worldwide scale, and natural products are now recognized as an acceptable source of molecules that exhibit antimicrobial activity (Rex et al., 2019). Medicinal applications of natural items, such as plants, animals, and microorganisms, date back centuries, and many of these natural products have shown the ability to inhibit the growth of bacteria. Natural products have various advantages over synthetic medications, including a lower potential for toxicity, a wider range of activity, and the ability to target multiple bacterial sites at the same time (Miethke et al., 2021). Essential oils, plant extracts, marine species, and microorganisms are only some examples of the natural goods that have been recognized as having the potential to be sources of antimicrobial chemicals (Kabir et al., 2022). It has been demonstrated that many of these natural compounds contain substantial antibacterial action against a wide variety of bacteria, including those that are resistant to multiple classes of antibiotics (Bloom et al.,2017; Theuretzbacher et al.,2020).

The utilization of natural products as a tactic to fight antimicrobial resistance (AMR) has garnered a growing amount of attention in the past few years (Micoli et al., 2021). Natural products have been utilized as lead compounds in the discovery of new

antibiotics, and it has been demonstrated that certain natural items can increase the efficacy of antibiotics that are already in use. In addition, natural products have the potential to be used in the development of complementary treatments that can circumvent the drawbacks of currently available antibiotics (Chandler, 2020).

In a nutshell antimicrobial resistance is a developing threat for public health that calls for immediate intervention. Antibiotics have been misused and overused, which has led to the development and spread of drug-resistant bacteria, which in turn has made it much harder to eradicate infectious infections (Ito et al., 2022). In recent decades, there has been an increase in the amount of focus placed on the use of natural goods as a tactic for tackling AMR. Natural products provide a promising supply of molecules that possess antimicrobial activity. To combat the worldwide issue of AMR and ensure that infectious diseases can be effectively treated, it is imperative that novel antimicrobial drugs be discovered and developed (Podolsky, 2018).

EPIDEMIOLOGY OF ANTIMICROBIAL RESISTANCE

Antimicrobial resistance (AMR) is a growing concern to the health of people all over the world and has been referred to as a "silent pandemic." Antimicrobial resistance is said to be the cause of around 700,000 fatalities around the world each and every year, as reported by the World Health Organisation (WHO). If nothing is done to address the issue, it is anticipated that by the year 2050, this figure will have increased to 10 million deaths annually (WHO, 2023). In addition, each year in the United States, at least 2.8 million individuals become infected with bacteria that is resistant to antibiotics, and as a direct result, the deaths of more than 35,000 people occur (CDC, 2022). Approximately 33,000 individuals lose their lives annually in Europe as a direct consequence of diseases brought on by germs that are resistant to antibiotics (ECDC, 2020). In many regions of the world, the prevalence of illnesses that are resistant to several medications is on the rise, with some nations estimating proportions of multidrug-resistant infections that are higher than fifty percent (WHO, 2018). The prevalence of antibiotic-resistant bacteria is significantly higher than in other regions of the world in particular parts of the globe, notably certain portions of Asia and Africa. For instance, the rates of antibiotic resistance in certain bacterial illnesses are as high as 70% in India. This is the case in India (Singh et al., 2018).

CHALLENGES

Antimicrobial resistance (AMR) is one of the most pressing global public health challenges, threatening the effectiveness of antibiotics and other antimicrobial agents. Addressing this issue involves complex hurdles spanning healthcare systems, governance, and public behavior. Below are some key challenges: (Wernli et al., 2017; Tyers and Wright, 2019; Landecker, 2019; Limmathurotsakul et al., 2019; Thornber et al., 2020).

Misuse and Overuse of Antimicrobials

a. Clinical Overprescription: Inappropriate prescribing practices, including antibiotics for viral infections, contribute significantly to AMR.

b. Self-medication: Easy access to over-the-counter antibiotics, especially in low- and middle-income countries, exacerbates misuse.

c. Agricultural Use: The widespread use of antimicrobials in livestock for growth promotion and disease prevention fuels resistance.

Lack of New Antimicrobials

a. Limited Pharmaceutical Investment: Developing new antibiotics is costly and yields limited financial returns, discouraging research and innovation in this field.
b. Regulatory Barriers: The lengthy approval processes for new drugs slow their availability.

Weak Surveillance Systems

a. Inconsistent Data Collection: Many countries lack robust systems to monitor AMR trends.
b. Global Disparities: Limited diagnostic facilities in resource-constrained settings hinder accurate detection and reporting.

Inadequate Infection Prevention

a. Poor Healthcare Practices: Insufficient hygiene and infection control in hospitals promote the spread of resistant pathogens.
b. Community Settings: Lack of awareness about proper hygiene practices further aggravates the problem.

Global Coordination Challenges

a. Policy Fragmentation: Differences in national AMR strategies create challenges in coordinated global action.
b. Cross-border Spread: Resistant pathogens do not respect borders, complicating containment efforts.

Public Awareness and Behavior

a. Limited Knowledge: Lack of understanding about AMR among the general public leads to improper antibiotic use.
b. Behavioral Resistance: Changing entrenched behaviors, such as over-reliance on antibiotics, is a major challenge.

Economic and Resource Constraints

a. High Costs of Interventions: Implementing robust AMR strategies requires significant investment in healthcare infrastructure, surveillance, and public health campaigns.
b. Impact on Marginalized Groups: Resource-poor communities are disproportionately affected by AMR due to limited access to quality healthcare.

WAY FORWARD

Tackling antimicrobial resistance (AMR) requires a comprehensive and coordinated approach that involves governments, healthcare providers, the pharmaceutical industry, agriculture, and the public. Below are elaborative strategies that provide a pathway to mitigate this global health threat: (Mendelson & Matsoso, 2015; Micoli et al., 2021 & Podolsky, 2018)

Strengthening Antimicrobial Stewardship

Antimicrobial stewardship refers to coordinated interventions designed to promote the appropriate use of antimicrobials. Key actions include:
a. Guidelines and Protocols: Establishing evidence-based treatment guidelines for the prudent use of antimicrobials in human and veterinary medicine.
b. Prescriber Training: Educating healthcare providers on diagnosing infections accurately and prescribing antibiotics only when necessary.
c. Monitoring Use: Implementing systems to track antibiotic prescriptions and usage patterns to identify areas of overuse or misuse.

Enhancing Surveillance Systems

Robust surveillance is critical to understanding AMR trends and identifying resistant pathogens.
a. Global Data Sharing: Establishing international networks to share data on AMR and antimicrobial usage, such as the WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS).
b. Diagnostic Capacity: Investing in diagnostic technologies, particularly in low-resource settings, to improve early detection and accurate reporting of resistant infections.
c. One Health Surveillance: Integrating data from human health, animal health, and the environment to monitor AMR comprehensively.

Promoting Research and Innovation

The development of new antibiotics, diagnostics, and vaccines is essential to outpace evolving resistance.
a. Incentives for Innovation: Providing financial incentives such as tax breaks, grants, and public-private partnerships to encourage pharmaceutical companies to invest in antibiotic research.
b. Alternative Therapies: Exploring non-antibiotic treatments such as bacteriophage therapy and immunotherapies as potential solutions.
c. Rapid Diagnostics: Supporting research into point-of-care diagnostic tools to distinguish bacterial from viral infections.

Improving Infection Prevention and Control

Reducing the incidence of infections minimizes the need for antimicrobials, thereby curbing resistance.
a. Healthcare Settings: Implementing strict infection control measures, such as hand hygiene, sterilization, and isolation protocols.
b. Community Settings: Promoting basic hygiene practices, such as clean water, sanitation, and vaccination, to reduce disease transmission.
c. Vaccination Programs: Expanding the use of vaccines to prevent bacterial infections (e.g., pneumococcal vaccine) and reduce the reliance on antibiotics.

Strengthening Regulatory Frameworks

Legislation and regulation play a crucial role in controlling antimicrobial misuse.
a. Over-the-Counter Restrictions: Enforcing laws to regulate the sale of antibiotics and

require prescriptions for their use.
b. Agricultural Regulations: Banning or limiting the use of antibiotics as growth promoters in livestock and ensuring that veterinary antibiotics are used responsibly.
c. Environmental Policies: Managing pharmaceutical waste to prevent environmental contamination that can drive resistance.

Raising Public Awareness

Educating the public about AMR is vital to fostering behavioral change.
a. Awareness Campaigns: Launching global and local campaigns to educate people about the dangers of AMR and the importance of responsible antibiotic use.
b. Community Engagement: Working with community leaders and influencers to promote antibiotic stewardship and hygiene practices.
c. School Education: Integrating AMR awareness into school curricula to build a culture of responsible antimicrobial use from an early age.

Enhancing Global Collaboration

AMR is a transnational issue requiring coordinated global efforts.
a. One Health Approach: Promoting collaboration across sectors, including human health, animal health, agriculture, and the environment, to address AMR comprehensively.
b. International Frameworks: Strengthening international agreements and action plans, such as the Global Action Plan on Antimicrobial Resistance by WHO.
c. Capacity Building: Supporting low- and middle-income countries in developing the infrastructure and expertise needed to combat AMR.

Sustainable Financing for AMR Strategies

Adequate and sustained funding is essential to implement AMR strategies effectively.
a. Global Funds: Establishing dedicated funds to support AMR-related initiatives, similar to the Global Fund for HIV/AIDS, Tuberculosis, and Malaria.
b. National Budgets: Allocating sufficient resources in national healthcare budgets for AMR surveillance, prevention, and treatment programs.
c. Public-Private Partnerships: Engaging the private sector to co-fund AMR research and public health campaigns.

RECOMMENDATIONS

AMR is a worldwide problem that has to be dealt with remedies that are customised to the local, national, and international levels by taking a holistic strategy and developing global collaboration. In order to do this, the problem must be approached at all three levels. It is necessary to make efforts that are both extensive and well-coordinated on all levels of society if we are to limit the progression of AMR (Ferri et al.,2017).

Finding an acceptable compromise between the conflicting interests and requirements of many constituencies is going to be one of the most significant problems that lie ahead. As a result, it is imperative that any proposed alternatives and suggestions linked to them be directed towards the following topics:
- Decision-makers and healthcare regulators
- Communities that are providing medical treatment for humans and animals

- Customers and organizations
- Companies (Ferri et al.,2017).

DECLARATIONS

Competing Interests

Author declares no conflict of interest.

Funding

No funds, grants, or other support was received.

REFERENCES

Aljeldah, M. M. (2022). Antimicrobial Resistance and Its Spread Is a Global Threat. Antibiotics, 11(8), 1082. https://doi.org/10.3390/antibiotics11081082

Bloom, G., Merrett, G. B., Wilkinson, A., Lin, V., & Paulin, S. (2017). Antimicrobial resistance and universal health coverage. BMJ Global Health, 2(4), e000518. https://doi.org/10.1136/bmjgh-2017-000518

Chandler, C. I. R. (2019). Current accounts of antimicrobial resistance: Stabilisation, individualisation and antibiotics as infrastructure. Palgrave Communications, 5(1), 53.

CDC, (2022). https://www.cdc.gov/drugresistance/about.html

Chokshi, A., Sifri, Z., Cennimo, D., & Horng, H. (2019). Global contributors to antibiotic resistance. Journal of Global Infectious Diseases, 11(1), 36. https://doi.org/10.4103/jgid.jgid_110_18

Darby, E. M., Trampari, E., Siasat, P., Gaya, M. S., Alav, I., Webber, M. A., & Blair, J. M. A. (2023). Molecular mechanisms of antibiotic resistance revisited. Nature Reviews Microbiology, 21(5), 280–295.

ECDC, (2020). https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2019

Ferri, M., Ranucci, E., Romagnoli, P., & Giaccone, V. (2017). Antimicrobial resistance: A global emerging threat to public health systems. Critical Reviews in Food Science and Nutrition, 57(13), 2857–2876. https://doi.org/10.1080/10408398.2015.1077192

Ito, H., Wada, T., Ichinose, G., Tanimoto, J., Yoshimura, J., Yamamoto, T., & Morita, S. (2022). Social dilemma in the excess use of antimicrobials incurring antimicrobial resistance. Scientific Reports, 12(1), 21084. https://doi.org/10.1038/s41598-022-25632-1

Kabir, H., Hasan, M. K., Tutul, A. H., Islam, M. S., Jamil, S., Das, B. C., ... & Mitra, D. K. (2022). Prevalence and Determinants of Antibiotic Self-Administration Among Adult Antibiotic Users: A Cross-Sectional Study. Patient preference and adherence, 2409-2421.

Kim, D.-W., & Cha, C.-J. (2021). Antibiotic resistome from the One-Health perspective: Understanding and controlling antimicrobial resistance transmission. Experimental & Molecular Medicine, 53(3), 301–309. https://doi.org/10.1038/s12276-021-00569-z

Landecker, H. (2019). Antimicrobials before antibiotics: War, peace, and disinfectants. Palgrave Communications, 5(1), 45. https://doi.org/10.1057/s41599-019-0251-8

Larsson, D. G. J., & Flach, C.-F. (2022). Antibiotic resistance in the environment. Nature Reviews Microbiology, 20(5), 257–269. https://doi.org/10.1038/s41579-021-00649-x

Limmathurotsakul, D., Dunachie, S., Fukuda, K., Feasey, N. A., Okeke, I. N., Holmes, A. H., Moore, C. E., Dolecek, C., van Doorn, H. R., Shetty, N., Lopez, A. D., & Peacock, S. J. (2019). Improving the estimation of the global burden of antimicrobial resistant infections. The Lancet Infectious Diseases, 19(11), e392–e398. https://doi.org/10.1016/S1473-3099(19)30276-2

Mendelson, M., & Matsoso, M. P. (2015). The World Health Organization Global Action Plan for antimicrobial resistance. South African Medical Journal, 105(5), 325. https://doi.org/10.7196/SAMJ.9644

Micoli, F., Bagnoli, F., Rappuoli, R., & Serruto, D. (2021). The role of vaccines in combatting antimicrobial resistance. Nature Reviews Microbiology, 19(5), 287–302. https://doi.org/10.1038/s41579-020-00506-3

Miethke, M., Pieroni, M., Weber, T., Brönstrup, M., Hammann, P., Halby, L., Arimondo, P. B., Glaser, P., Aigle, B., Bode, H. B., Moreira, R., Li, Y., Luzhetskyy, A., Medema, M. H., Pernodet, J.-L., Stadler, M., Tormo, J. R., Genilloud, O., Truman, A. W., … Müller, R. (2021). Towards the sustainable discovery and development of new antibiotics. Nature Reviews Chemistry, 5(10), 726–749. https://doi.org/10.1038/s41570-021-00313-1

Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., Johnson, S. C., Browne, A. J., Chipeta, M. G., Fell, F., Hackett, S., Haines-Woodhouse, G., Kashef Hamadani, B. H., Kumaran, E. A. P., McManigal, B., … Naghavi, M. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet, 399(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0

Nathan, C. (2020). Resisting antimicrobial resistance. Nature Reviews Microbiology, 18(5), 259–260. https://doi.org/10.1038/s41579-020-0348-5

Podolsky, S. H. (2018). The evolving response to antibiotic resistance (1945–2018). Palgrave Communications, 4(1), 124. https://doi.org/10.1057/s41599-018-0181-x

Rex, J. H., Fernandez Lynch, H., Cohen, I. G., Darrow, J. J., & Outterson, K. (2019). Designing development programs for non-traditional antibacterial agents. Nature Communications, 10(1), 3416. https://doi.org/10.1038/s41467-019-11303-9

Theuretzbacher, U., Outterson, K., Engel, A., & Karlén, A. (2020). The global preclinical antibacterial pipeline. Nature Reviews Microbiology, 18(5), 275–285. https://doi.org/10.1038/s41579-019-0288-0

Thornber, K., Verner-Jeffreys, D., Hinchliffe, S., Rahman, M. M., Bass, D., & Tyler, C. R. (2020). Evaluating antimicrobial resistance in the global shrimp industry. Reviews in Aquaculture, 12(2), 966–986. https://doi.org/10.1111/raq.12367

Tiseo, K., Huber, L., Gilbert, M., Robinson, T. P., & Van Boeckel, T. P. (2020). Global Trends in Antimicrobial Use in Food Animals from 2017 to 2030. Antibiotics, 9(12), 918. https://doi.org/10.3390/antibiotics9120918

Van Boeckel, T. P., Brower, C., Gilbert, M., Grenfell, B. T., Levin, S. A., Robinson, T. P., Teillant, A., & Laxminarayan, R. (2015). Global trends in antimicrobial use in food animals. Proceedings of the National Academy of Sciences, 112(18), 5649–5654.

WHO, (2023). https://www.who.int/health-topics/antimicrobial-resistance#tab=tab_1

Wernli, D., Jørgensen, P. S., Morel, C. M., Carroll, S., Harbarth, S., Levrat, N., & Pittet, D. (2017). Mapping global policy discourse on antimicrobial resistance. BMJ Global Health, 2(2), e000378.